Uterine Cervical Neoplasms

66 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Uterine Cervical Neoplasms
Treatment and conditionWhere it standsTrials
Adaptive Hypofractionated Radiotherapy for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AK105 and anlotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
B1962 for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + NIMOTUZUMAB + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brachytherapy + External Beam Radiotherapy (EBRT) + placebo for Nimotuzumab + CISPLATIN for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cadonilimab for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
camrelizumab; famitinib malate for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + FAMITINIB L-MALATE + CAMRELIZUMAB for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy + Hypofractionated external beam radiation + Image-guided brachytherapy for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
concurrent chemotherapy + Definitive hypofractionated intensity-modulated radiation theraphy for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gecacitinib + ZG005 + BEVACIZUMAB for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JSKN033 + BEVACIZUMAB + PLATINUM for uterine cervical neoplasmsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
paclitaxel combined with platinum for uterine cervical neoplasmsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
radical surgery + CAMRELIZUMAB + Paclitaxel + CISPLATIN for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sacituzumab tirumotecan for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Serplulimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SHR-A1811 Injection for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for uterine cervical neoplasmsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tretinoin for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for uterine cervical neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1